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Abstract 
Eltrombopag (ELT), an oral thrombopoietin receptor agonist, has recently emerged as a promising new drug for the treatment of 
aplastic anemia (AA). How ELT is used outside of clinical trials in the real-world setting and results of this treatment are not 
known. We conducted therefore a retrospective survey on the use of ELT in AA among EBMT member centers. We analyzed the 
134 patients reported in our survey together with 46 patients recently published by Lengline et al. The median follow-up from 
start of ELT treatment was 15.3 months, with 85.6% patients alive at last follow-up. Importantly, only 28.9% of our patients 
received ELT according to the FDA/EMA label as monotherapy in the relapsed/refractory setting, whereas 16.7% received ELT 
upfront. The overall response rate in our cohort was 62%, very similar to the results of the pivotal ELT trial. In multivariate 
analysis, combination therapy with ELT/cyclosporine/ATG and response to previous therapy were associated with response. 
Overall survival was favorable with a 1-year survival from ELT start of 87.4%. We identified age, AA severity before ELT start 
and response to ELT as variables significantly associated with OS. Two patients transformed to MDS; other adverse events were 
mostly benign. In sum, ELT is used widely in Europe to treat AA patients, mostly in the relapsed/refractory setting. Response to 
 
 
1 
Department of Hematology, University Hospital Basel, Petersgraben 
4, 4031 Basel, Switzerland 
2 Hopital St. Louis, Paris, France 
3 
EBMT Data Office, Leiden, Netherlands 
4 First State Pavlov Medical University of St. Petersburg, St. 
Petersburg, Russia 
5 Dimitri Rogachev Federal Research Center for Pediatric 
Hematology, Oncology and Immunology of Russian Federation, 
Moscow, Russia 
6 University of Heidelberg, Heidelberg, Germany 
7 Leiden University Hospital, Leiden, Netherlands 
8 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, and 
University of Milan, Milan, Italy 
9 Hôpital Emile Muller, Mulhouse, France 
10 
Division of Hematology, Department of Translational Medicine, 
University of Eastern Piedmont, Novara, Italy 
11 S.S.C.V.D Trapianto di Cellule Staminali, Torino, Italy 
12 Ospedale Civile, Pescara, Italy 
13 
Institute Giannina Gaslini, Genoa, Italy 
14 University Hospital Center and Medical School, University of 
Zagreb, Zagreb, Croatia 
15 Clinical Hematology, CHU Nantes, Nantes, France 
16 Karolinska University Hospital, Stockholm, Sweden 
17 
S.Orsola-Malpighi Hospital, Bologna University, Bologna, Italy 
18 Fondazione Policlinico Universitario A. Gemelli-IRCCS, 
Rome, Italy 
19 CHU ESTAING, Clermont, France 
20 Ospedale San Gerardo, Monza, Italy 
21 
Department of Hematology and Central Hematology Laboratory, 
Inselspital, Bern University Hospital, University of Bern, 
Bern, Switzerland 
22 
Hematology, Department of Clinical Medicine and Surgery, Federico 
II University of Naples, Naples, Italy 
  
 
ELT is similar to the clinical trial data across different age groups, treatment lines, and treatment combinations and results in 
favorable survival. 
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Introduction 
 
Severe aplastic anemia (SAA) is a rare heterogenous disease 
mostly autoimmune, in which T cell attack on hematopoietic 
stem (HSCs) and progenitor cells results in progressive bone 
marrow failure [1]. In patients not selected for potentially cu- 
rative allogeneic hematopoietic stem cell transplantation (allo- 
HSCT), the standard therapy consists of immunosuppression 
(IS) with horse anti-thymocyte globulin (ATG) and cyclospor- 
ine A (CYA) [2]. About 70% of patients do respond, but 
survival with good marrow function without relapse is in the 
order of only 30–40% [3]. Treatment options are unsatisfac- 
tory for patients refractory to or relapsing after first-line treat- 
ment and not eligible for allo-HSCT from a matched unrelated 
donor, with response rates to an additional course of ATG or 
anabolic steroids in the order of 30–60% [4–6]. In addition to 
the modest efficacy, repeated courses of iimunosuppression 
(IS) may predispose to secondary malignancies [7]. 
Furthermore, the intensive immunosuppressive ATG-CYA 
combination cannot be applied in a proportion of AA patients 
due to advanced age or contraindications such as active infec- 
tion [8]. 
Eltrombopag (ELT), a small molecule thrombopoietin 
(TPO) mimetic has been introduced in the AA therapy arma- 
mentarium recently. In contrast to previous failed attempts to 
stimulate the HSC compartment by diverse growth factors 
such as G-CSF, GM-CSF, or EPO [3, 9], ELT induced trilinear 
hematopoietic responses in refractory SAA patients [10]. 
Mechanistically, ELT binds to the TPO receptor c-MPL 
expressed on HSCs and leads to their proliferation and expan- 
sion [11, 12], although additional, immune modulatory effects 
might also be involved [13]. Results of a phase II trial exam- 
ining ELT monotherapy in refractory SAA patients showing a 
40% response rate [10, 14] led to the approval of ELT as 
monotherapy in relapsed-refractory SAA in the USA and 
Europe [15, 16]. Recently, increased response rate to ELT in 
combination with standard ATG-CYA immunosuppression as 
compared to historical controls has been reported by the NIH 
group [17] and the use of ELT in the first-line setting is cur- 
rently being tested in several ongoing clinical trials. Less is 
known about the use of ELT outside clinical trials. So far, real- 
world data of two cohorts described robust response to ELT 
administered as monotherapy or part of various combination 
regimens [18–20]. Romiplostim is a peptide-analogue TPO 
agonist with a very different chemical structure and different 
 
binding site on MPL, but similar efficacy as ELT in immune 
thrombocytopenia (ITP) [21]. Although romiplostim has been 
shown also to stimulate HSCs in animal models [11], its use in 
SAA remains anecdotal [19]. As in ITP switch from one TPO 
agonist to the other in refractory patients results in a high 
response rate [22], exploration of romiplostim for the treat- 
ment of SAA patients is clearly warranted. 
Although the first results on ELT in SAA are promising, its 
optimal use, the necessity for concomitant IS, as well as pre- 
dictors of response or incidence of relapse remain unknown, 
particularly for patients not representative of the clinical trial 
population or treated outside of the FDA/EMA label. 
Similarly, some safety concerns about clonal evolution and 
transformation to myelodysplastic syndromes in patients on 
ELT remain [14]. Analysis of a large cohort of SAA patients 
treated with ELT outside clinical trials is likely to give valu- 
able insight into these open questions. Therefore, the EBMT 
SAA working party conducted a Europe-wide survey on the 
use of TPO agonists to treat AA in member centers. Here we 
report the results of the largest cohort of ELT treated AA 
patients so far. 
 
 
 
Methods 
Data collection 
 
The EBMT SAA working party invited 441 EBMT centers to 
participate in this survey, 103 (23%) centers answered, 92 
(21%) accepted to participate. Fifty centers (11%) with poten- 
tially eligible patients received the survey form (supplemen- 
tary material) based on the EBMT minimal-essential data 
(MED) B+C forms used to record SAA patients in the 
EBMT registry. Patients with AA (moderate, severe, very se- 
vere) or PNH with AA phenotype treated with TPO agonists 
(ELT or romiplostim) either as first-line treatment or as rescue 
treatment outside clinical study protocols could be included in 
the survey. We considered ELT as first-line treatment if it was 
started within 60 days from beginning of the first therapy. 
Rescue treatment includes patients refractory or with insuffi- 
cient response to one or several initial line(s) of therapy. 
Relapse includes patients who lost their response to any pre- 
vious therapy, including those failing initial IS therapy for 
relapse. 
  
(c) 
 
 
 
Complete response (CR) was defined as recovery of blood 
counts (hemoglobin > 100 g/l, neutrophil count > 1.5 × 10
6
/ 
ml, platelet count > 100 × 10
6
/ml). Partial response (PR) was 
defined as transfusion independence with any degree of im- 
provement of blood counts. Minimal response was defined as 
some improvement in one or more lineage but not fulfilling 
the criteria of PR. No response refers to patients not fulfilling 
any of the above criteria. 
We received data on 137 patients from 31 EBMT centers. 
In addition, we obtained individual patient level data from the 
French Reference Center for Aplastic Anemia on ELT-treated 
SAA patients published recently [20]. As the two cohorts had 
very similar inclusion/exclusion criteria, the two cohorts were 
merged in a single database (total 183 patients from 46 cen- 
ters, median number of patients per center 2, range 1–21). 
 
Data analysis 
 
Due to low numbers (n = 3), patients treated with romiplostim 
were not considered further. Analyses were conducted on all 
ELT treated patients (n = 180). 
Descriptive statistics are presented as percent of all patients 
with available data. Categorical data were compared using the 
Chi-square test, continuous variables were analyzed using the 
Kruskal-Wallis non-parametric test. Survival is presented using 
the Kaplan-Meier estimator. Comparisons among groups were 
by the log-rank test, multivariate models were created using the 
Cox regression model including response to ELT as a time- 
dependent covariate. Response to ELT was analyzed as cumula- 
tive incidence with death as a competing event. Univariate com- 
parisons were done using the Gray test and multivariate models 
were built according to Fine and Gray [23] using EZR software 
[24]. A p value of < 0.05 was considered significant. 
 
 
Results 
Use of ELT for AA in Europe 
 
Treatment episodes started from 11/2011 to 10/2017. The me- 
dian follow-up from start of ELT treatment was 15.3 months 
(95% CI 13–17.6 months), with 85.6% patients alive at last 
follow-up. All patients were treated with ELT, in a median and 
maximum dose of 150 mg/day, 11 patients (6.4%) received a 
higher dose up to 450 mg. ELT dose was not different in 
patients with or without a response. ELT was ongoing in 
50% of patients alive at last follow-up. 
A minority of patients (n = 30, 16.7%) received ELT upfront, 
i.e., within 60 days following initiation of first-line treatment, 
whereas most patients were treated with ELT as a rescue treat- 
ment either for refractory disease or relapse (Fig. 1a). ELT was 
applied both as monotherapy and in combination with IS with 
CYA ± ATG (Fig. 1b). Based on this information, different 
(a) 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Patterns of ELT use. a Treatment line, b combination regimens, 
and c treatment groups 
 
associations with ELT are represented in our study population 
(Fig. 1c). Importantly, 71.1% of patients received ELT outside 
the FDA/EMA label, either in the first-line setting or as part of a 
combination therapy (irrespective of the therapy line). There 
was a significant (p < 0.001) association between treatment line 
and ELT combination, as the proportion of patients treated with 
ELT alone increased form first-line treatment to relapse, where- 
as ELT-CYA-ATG was used predominantly in the first-line set- 
ting (Table 1). Overall, 23 (12.8%) patients received ELT in 
combination with CYA-ATG (within 60 days of 1st ATG 
day), starting at day 14 (median) from the first ATG dose. 
  
 
Table 1 ELT treatment combinations according to treatment line 
p < 0.001 Treatment line 
  
p value from chi-square test 
 
Baseline characteristics 
 
Baseline characteristics of the whole cohort are shown in 
Table 2. Most patients were dependent on RBC and PLT 
transfusions (93.3% and 90%, respectively) preceding ELT 
therapy. Interestingly, the choice of the ELT treatment combi- 
nation (monotherapy vs. combination therapy) can be at least 
partly explained by differences in age or AA severity, as pa- 
tients treated with ELT monotherapy were older and were 
more likely to present with moderate AA at diagnosis com- 
pared to patients treated with combination therapy (p =< 001 
and p = 0.069, respectively, supplementary Table 1). 
 
Response 
 
The reported overall response rate in our cohort was 62%, 
with 17.9% CR, 26.8% PR, and 17.3% minimal response. In 
patients responding, best response was achieved in median 
after 224 days (95% confidence interval 136.5–311.5 days) 
(Fig. 2), although responses were reported at considerably 
later time points (range 8–1335 days). Time to first response 
was likely shorter, as response depth likely increases over 
time, but this information was not assessed in the survey. 
Twenty-four patients (21.6% of responding) stopped ELTafter 
 
 
Fig. 2 Time to best response 
 
having achieved a stable response, four (16.7%) relapsed in 
median 83 days (range 53–980) following response and in 
median 246 days (range 164–988 days) after start of ELT. 
Overall, relapse occurred in 15 patients (14.7% of patients 
responding), in median 181 days (95% CI 162.7–199.3 days) 
after start of ELT. The median duration of response was not 
reached. 
The response rate did not differ between treatment combi- 
nations (p = 0.774), treatment line (p = 0.33) or according to 
treatment groups shown in Fig. 1c (p = 0.699). We analyzed 
thus our cohort as a whole and sought to identify factors 
predicting response in a time-to-event manner. 
In univariate models, we could not identify any baseline 
characteristic associated with response in the whole cohort, 
although severity of AA at diagnosis and at the time of ELT 
start, as well as first-line treatment were significantly associ- 
ated with death without a response (Tables 3 and 4, Fig. S1). 
In the multivariate model, combination therapy was a predic- 
tor (p = 0.04) of response, with a hazard ratio for response of 
2.95 (95% CI 1.28–6.83, p = 0.01) for the ELT/CYA/ATG 
 
Table 2 Baseline characteristics 
 
 
Sex  Age at start ELT, years, median (IQR) 48.4 (23.3–67) 
Male 56.1% Severity of AA at start ELT 
Female 43.9% Moderate 16.8% 
Age at diagnosis, years, 
median (IQR) 
43.4 (20–65.5) Severe 64.7% 
Severity of AA at diagnosis Very severe 17.9% 
Moderate 13.5% Number of previous treatment lines, 
median (IQR) 
Severe 55.6% Days from diagnosis to ELT start, 
median (IQR) 
Very severe 30.4% Days from last treatment to ELT start, 
median (IQR) 
PNH clone 18.9% Days from last ATG to ELT start, 
median (IQR) 
1 (1–2) 
 
348.5 (195–1212) 
 
140 (53–429) 
 
14 (7–20.5) 
 
 
ELT combination First-line Rescue treatment Relapse treatment 
 n = 30 n = 124 n = 26 
ELT 23.3% 33.1% 42.3% 
ELT+CyA 30% 58.1% 53.8% 
ELT+CyA/ATG 43.3% 7.3% 3.8% 
ELT+other 3% 1.6% 0% 
 100% 100% 100% 
 
  
 
Table 3 Univariate analysis of response with death as a competing event 
Univariate analysis (Gray test) for competing events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
group compared to ELT monotherapy (Tables 3 and 4). In the 
subgroup of patients with previous therapy, response to previ- 
ous therapy was a predictor of response to subsequent ELT 
treatment (HR 1.689, 95% CI 1.04–2.75, p = 0.04), whereas 
previous exposure to ATG, interval from diagnosis or interval 
from last treatment were not significantly associated with re- 
sponse (Tables 3 and 4). 
 
Survival 
 
The median survival was not reached, the 1-year survival from 
start of ELTwas 87.4% (95% CI 81.9–92.9%) (Fig. 3a). Of the 
26 patients who died during follow-up, seven (26.9%) had 
undergone allo-HSCT and in six of these, deaths were 
 
classified as HSCT-related. In univariate and multivariate 
analysis, age at ELT start, and AA severity before ELT start 
were significantly associated with OS. Response to ELT in- 
cluded as a time-dependent covariate was similarly correlated 
with a lower incidence of death (Tables 5 and 6, Fig. 3b). 
 
 
Safety 
 
Adverse events were reported in 51 patients, although severe 
(grade III-IV) AEs were rare (17 patients, 30.4% of all AEs). 
The most frequent AE was hepatic toxicity, a well-known side 
effect of ELT (Table 7). Skin reactions were rare. Importantly, 
ELT was stopped only in four patients due to AEs. 
Event: n= Response 
   
Death 
 
  
1-year incidence 95% CI p value 
 
1-year incidence 95% CI p value 
All patients 
        
Combination    0.15    0.163 
Monotherapy 50 0.47 0.31–0.61   0.12 0.04–0.24  
ELT + Cya 91 0.61 0.5–0.71   0.05 0.02–0.11  
ELT + CyA/ATG 23 0.66 0.4–0.83   0.15 0.03–0.36  
Treatment line         
First-line 26 0.48 0.26–0.67 0.43  0.26 0.1–0.47 < 0.001 
Rescue treatment 116 0.59 0.49–0.68   0.05 0.02–0.11  
Relapse treatment 25 0.56 0.32–0.73   0.05 0.003–0.22  
Sex         
Male 93 0.55 0.43–0.64 0.29 0.08 0.03–0.15 0.77 
Female 74 0.6 0.47–0.71  0.09 0.04–0.17  
AA severity at diagnosis    0.5   < 0.001 
Moderate 23 0.59 0.35–0.77  0.04 0.003–0.19  
Severe 88 0.57 0.46–0.68  0.03 0.01–0.08  
Very severe 47 0.55 0.37–0.69  0.21 0.1–0.36  
AA severity at ELT start         
Moderate 28 0.66 0.44–0.81 0.42   < 0.001 
Severe 106 0.58 0.47–0.67  0.03 0.01–0.1  
Very severe 27 0.4 0.21–0.59  0.38 0.16–0.6  
Etiology        
AA 137 0.58 0.48–0.66 0.9 0.09 0.05–0.15 0.5 
PNH 30 0.56 0.34–0.72  0.04 0.002–0.17  
Patients with previous treatment         
ATG-exposed    0.91   0.84 
No 41 0.58 0.39–0.74  0.03 0.002–0.12  
Yes 100 0.59 0.48–0.68  0.06 0.02–0.12  
Response to previous therapy    0.02   0.34 
No 98 0.533 0.42–0.63  0.06 0.02–0.13  
Yes 34 0.722 0.53–0.85  0.031 0.002–0.14  
 
  
 
Table 4 Multivariate analysis of 
response with death as a 
competing event 
 
 
Multivariate analysis for response or death as competing events (Fine and Gray) 
 
 
HR for response 95% CI p value 
 
 
All patients (n = 155 evaluable) 
Combination Overall (Wald test):0.04 
Monotherapy 1 (reference) 
ELT+CYA 1.36 0.77–2.4 0.29 
ELT+CYA/ATG 2.95 1.28–6.83 0.01 
Treatment line Overall (Wald test): 0.16 
 
First-line 1 (reference)  
Rescue treatment 1.96 0.91–4.2 
Relapse treatment 2.51 0.94–6.7 
Sex   
Male 1 (reference)   
Female 1.08 0.69–1.67  
AA severity at diagnosis   Overall (Wald test):0.72 
Moderate 1 (reference)   
Severe 1.46 0.59–3.61  
Very severe 1.47 0.51–4.2  
AA severity at ELT start   Overall (Wald test): 0.52 
Moderate 1 (reference)   
Severe 0.67 0.3–1.49  
Very severe 0.54 0.1842–1.59  
Etiology    
AA 1 (reference)   
PNH 0.78 0.41–1.45  
Age at ELT start 1.01 1.0–1.02  
Patients with previous treatment (n = 123 evaluable) 
ATG-exposed 
No 1 (reference)  
Yes 0.853 0.46–1.57 0.61 
Response to previous therapy 
No 1 (reference)   
Yes 1.689 1.04–2.75 0.035 
Time from diagnosis to ELT start 0.9998 0.9995–1 0.28 
Time from last treatment to ELT start 1 0.9999–1 0.16 
 
 
Cytogenetic abnormalities were assessed at diagnosis 
and showed a normal karyotype in 123 patients (91.1%) 
and an  abnormal karyotype  in  12  cases (8.9%) including 
3 cases of trisomy 8, 2 cases  of  monosomy  7,  and  1  
case of inv. (3;3q26). Cytogenetic information was not 
available for the remaining cases (n = 45, 25% of the 
whole cohort). Cytogenetic evolution  during  the  course 
of the treatment was not assessed in  the  survey.  Only  
two cases of transformation into myelodysplastic syn- 
drome  (MDS)  were  described,  diagnosed  2   and 
5.5 months after ELT start. One of these two  patients  
with a subsequent MDS transformation had  a  monoso- 
my X at AA diagnosis, the other had no cytogenetic 
information available. No other secondary malignancies 
apart from two cases of squamous cell carcinoma of the 
skin occurred. 
 
 
Discussion 
 
Whereas IS addresses the autoimmune destruction of HSCs, 
allo-HSCT has been so far the only treatment modality 
correcting also the resulting stem cell defect in AA patients. 
The efficacy of ELT as monotherapy, presumably acting pref- 
erentially at the stem cell level, created much excitement in the 
field. The next logical step, combining ELT with IS has been 
  
(a) 
 
 
 
 
 
 
(b) 
 
Table 6 Multivariate analysis of survival 
Multivariate analysis for OS 
Variable p value HR for death 0.95 CI 
 
 
Age at start ELT 0.01 1.026 1.005 1.046 
AA severity at ELT start 0 
Moderate 
Severe 0.49 1.7 0.4 7.9 
Very severe 0.001 13.2 2.7 64 
ELT combination 0.56 
ELT 
ELT+CYA 
ELT+CYA/ATG 
Response to ELT 0.01 
Yes (compared to none) 0.11 0 0.7 
 
 
 
 
 
 
 
Fig. 3 Overall survival. a Whole cohort, b according to response to ELT, 
please refer also to the multivariate analysis of survival considering 
response to ELT as a time-dependent covariate 
 
 
explored in phase II trials [17, 25] and is being examined in 
several ongoing phase III trials. Until the role of ELT in the 
first-line setting is clearly defined, ELT will be used mostly in 
patients relapsed or refractory to IS or allo-HSCT. 
 
 
 
In line with this, only a small minority in our cohort was 
treated upfront with an ELT containing regimen. Although the 
reasons for ELT application in the first-line setting were not 
evident, age and comorbidities precluding use of standard 
ATG/CYA therapy leading to ELT use as part of a low inten- 
sity therapy on one hand and high-risk AA resulting in ELT in 
combination with ATG/CYA on the other are likely explana- 
tions. Supporting this hypothesis, the median age of patients 
treated with ELT alone or with CYA in the first-line setting 
was 55.5 years, compared to 23 years (p < 0.001) in patients 
treated with ELT/CYA/ATG. Severity of AA at diagnosis was 
similar. Since this is likely a selection of patients and is not 
representative of the entire patient population, the role of ELT 
in the first-line setting could not be clarified in our cohort. The 
response rate of 46.7% in patients with low intensity ELT 
treatment in the first-line setting is certainly meaningful, but 
not above the range expected, e.g., with CYA alone [26]. 
In our cohort, relapsed/refractory patients were treated with 
ELT mostly in combination with CYA ± ATG, unlike in the 
pivotal trial using ELT as a monotherapy [14]. Although fail- 
Table 5 Univariate analysis of survival 
ure of IS argues against retreatment with another course of IS 
 
 
Univariate analysis for OS (log-rank test) 
   Table 7 Adverse events 
Variable p value 
   Adverse events 
Sex 0.62 
Grades I–II Grades III–IV Any grade 
 
 
 
 
 
 
 
 
 
AA severity at diagnosis 0.17  
Age at start ELT 0.01 Bleeding 10.3% 18.8% 12.7% 
PNH 0.11 Infection 5.1% 31.3% 12.7% 
AA severity at ELT start < 0.001 Hepatic toxicity 64.1% 25.0% 52.7% 
ELT combination 0.55 Skin 0.0% 12.5% 3.6% 
Treatment line 0.1 Other 20.5% 18.8% 18.2% 
Prev. ATG exposure 0.92 n= (events) 39 17 56 
Best response to previous treatment 0.65  
The number and pe 
 
rcentage of AE 
 
s corresponds to the 
 
events reported 
 
  
 
with ATG from as different source, alemtuzumab or an alter- 
native calcineurin inhibitor, this strategy results in a response 
rate up to 50–80% [6, 27]. A detailed analysis of therapies 
preceding ELT was beyond the scope of our survey; we were 
therefore unable to discern whether patients benefitted from 
continuation of IS after insufficient response or retreatment 
with CYA /− ATG in relapse. Interestingly, a response to pre- 
vious IS was a predictor of response to ELT only in patients 
treated with ELT in combination with IS, but not with ELT 
monotherapy. This might support independent predictive fac- 
tors for response between IS and ELT, although differences in 
the number of patients in the two groups provides an alterna- 
tive explanation. For CYA/ATG, several biological predictors 
of response, such as absolute reticulocyte count reflecting 
stem cell reserve or lymphocyte count and presence of a 
PNH clone reflecting the level of the immune attack have been 
defined [28, 29]. Such variables were not systematically que- 
ried in our survey, but clinical parameters might provide an 
approximation of these predictors. Age and time from diagno- 
sis to ELT treatment, as proxy for stem cell reserve, were not 
negatively correlated with response. Similarly, presence of a 
PNH clone or treatment of relapse following IS, arguing for a 
predominant autoimmune etiology, did not affect response 
rates. Finally, severity of AA at ELT start could also not pre- 
dict response, although it did correlate with death without 
response in competing risk analysis. It is unlikely, that merely 
increasing the size of such retrospective cohorts can discern 
predictors of response. Additional mechanistic studies in pre- 
clinical models as well as correlative analyses in uniformly 
treated patients in clinical trials will answer these urgent ques- 
tions. Compared to the response used in current clinical trials, 
our more traditional response criteria did not assess trilineage 
response. Since almost all patients were RBC transfusion de- 
pendent, PR or CR to ELT essentially implies an erythroid 
response and rules out an isolated increase of platelets upon 
ELT treatment. In our multivariate analysis, combination ther- 
apy compared to ELT monotherapy was associated with a 
better response; this difference was driven mainly by the better 
response in the ATG combination group. Multivariate analy- 
ses can control for some confounding factors; these results 
must be interpreted cautiously in light of the very different 
patient characteristics. 
Although the use of a second-line therapy such as ELT 
likely identifies patients with a less than average prognosis, 
the overall survival in our cohort was favorable. A consider- 
able proportion of patients died due to allo-HSCT-related 
causes and not from progression of AA. Whereas traditionally 
AA patients have been treated in allo-HSCT centers, ELT 
might be also applied nowadays in less-specialized centers 
not included in our survey and thus introducing bias particu- 
larly in this regard. The association between response and 
survival is inherently biased particularly in retrospective stud- 
ies. Despite this limitation, response to ELT considered as a 
time-dependent variable in the multivariate Cox model was 
significantly associated with better survival, underscoring the 
importance of response. 
Retrospective analyses likely underreport low-grade AEs, 
but the large number of patients is useful to detect rare, severe 
AEs of novel drugs. AEs in our survey were consistent with 
the favorable safety profile in AA trials and ITP patients, with 
common hepatic toxicity and a few cases of skin reactions. 
Although cytogenetic evolution was not systematically 
assessed in our survey, the low rate of MDS diagnosis (inci- 
dence of ~ 1 in 120 years of follow-up) is a reassuring signal, 
particularly since 6.7% of all patients had a cytogenetic abnor- 
mality before ELT treatment. 
Additional limitations of our study include those associated 
with retrospective cohorts such as selection bias, recall bias, 
incomplete data, and limited follow-up. Conversely, the co- 
hort represents real-world data from different countries across 
Europe. This is particularly important in a rare disease such as 
SAA with very different treatment trajectories often underrep- 
resented in clinical trials. Along the same lines, the majority of 
the patients in our cohort received ELT outside of the EMA/ 
FDA label and our data clearly supports this clinical practice. 
Our survey is in line with previous, considerably smaller 
cohorts of AA patients treated with ELT. Gill et al. [19] re- 
ported initially a cohort of ten refractory AA patients from 
Hong Kong treated with ELT alone or in combination with 
CYA. The study was recently updated with a longer follow-up 
and inclusion of additional patients [18]. Interestingly, the 
response rate of ten patients in the expansion cohort receiving 
ELT in the first-line setting was 90% compared to 50% in 
refractory patients. The higher response was not explained 
by the use of ATG in in the first-line patients, as all first-line 
patients treated with ELT/CYA without ATG responded. We 
could not confirm the higher response rate in patients treated 
upfront with ELT. 
Similar results were observed in a group of 46, mostly 
relapsed or refractory patients from France [20]. Transfusion 
independence was achieved in 36% and 49% in ATG naïve 
and ATG pretreated patients, respectively. These 46 patients 
are notably contained in our analysis. In our whole cohort, 
47.6% achieved at least a PR and thus transfusion indepen- 
dence. In contrast to the French cohort, there was no differ- 
ence in time to response in patients with a response in the first- 
line vs. rescue/relapse setting. 
In summary, ELT is already widely used in Europe among 
EBMT centers mostly as treatment for insufficient response to 
previous therapies or as relapse treatment. In contrast to the 
available clinical trial data, ELT is applied mostly in combi- 
nation with CYA. The response rate was consistent across all 
treatment situations and was similar across combinations. The 
results of ongoing clinical trials with ELT in the first-line 
setting, as well as mechanistic studies investigating synergism 
between ELT and IS are eagerly awaited. 
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